Funder
German Research Foundation
Reference10 articles.
1. Backer V., Sjöbring U., Sonne J., Weiss A., Hostrup M., Johansen H.K., et al. A randomized, double-blind, placebo-controlled phase 1 trial of inhaled and intranasal niclosamide - a broad spectrum antiviral candidate for treatment of COVID-19 the lancet regional health - Europe (in press). 2021. DOI: https://doi.org/10.1016/j.lanepe.2021.100084
2. Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects;Jurgeit;PLoS Pathog.,2012
3. Drug repurposing: the anthelmintics niclosamide and nitazoxanide are potent TMEM16A antagonists that fully bronchodilate airways;Miner;Front Pharmacol,2019
4. TMEM16A in cystic fibrosis: activating or inhibiting?;Kunzelmann;Front Pharmacol,2019
5. Niclosamide repurposed for the treatment of inflammatory airway disease;Cabrita;JCI Insight,2019
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献